269 related articles for article (PubMed ID: 29628176)
1. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
[TBL] [Abstract][Full Text] [Related]
2. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
3. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia.
Luyt CE; Aubry A; Lu Q; Micaelo M; Bréchot N; Brossier F; Brisson H; Rouby JJ; Trouillet JL; Combes A; Jarlier V; Chastre J
Antimicrob Agents Chemother; 2014; 58(3):1372-80. PubMed ID: 24342638
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
5. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
[TBL] [Abstract][Full Text] [Related]
7. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
[TBL] [Abstract][Full Text] [Related]
10. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients.
Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
Adv Exp Med Biol; 2013; 788():109-16. PubMed ID: 23835967
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
12. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Gimeno C; Cantón R; García A; Gobernado M;
Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
[TBL] [Abstract][Full Text] [Related]
13. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-Nonsusceptible
Asempa TE; Nicolau DP; Kuti JL
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31118271
[No Abstract] [Full Text] [Related]
16. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
17. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
[TBL] [Abstract][Full Text] [Related]
18. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD
Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
